Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Gucalp A, et al. Among authors: nabell l. Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21. Clin Cancer Res. 2013. PMID: 23965901 Free PMC article. Clinical Trial.
A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS. Miller KD, et al. Among authors: nabell l. Breast Cancer Res Treat. 2014 Nov;148(1):99-106. doi: 10.1007/s10549-014-3131-3. Epub 2014 Sep 26. Breast Cancer Res Treat. 2014. PMID: 25257727 Free PMC article. Clinical Trial.
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK. Van Swearingen AED, et al. Among authors: nabell l. Breast Cancer Res Treat. 2018 Oct;171(3):637-648. doi: 10.1007/s10549-018-4852-5. Epub 2018 Jun 25. Breast Cancer Res Treat. 2018. PMID: 29938395 Free PMC article. Clinical Trial.
Less Toxic Chemotherapy in Locally Advanced Breast Cancer.
Carpenter J, Forero A, Falkson CI, Nabell LM, De Los Santos JF, Krontiras H, Bland KI, Li Y, Bae S. Carpenter J, et al. South Med J. 2020 Nov;113(11):559-563. doi: 10.14423/SMJ.0000000000001169. South Med J. 2020. PMID: 33140109 Free PMC article.
Invasive breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Carlson RW, et al. Among authors: nabell lm. J Natl Compr Canc Netw. 2007 Mar;5(3):246-312. doi: 10.6004/jnccn.2007.0025. J Natl Compr Canc Netw. 2007. PMID: 17439758 Review. No abstract available.
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF. Forero-Torres A, et al. Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035. Clin Breast Cancer. 2010. PMID: 20705559 Free PMC article. Clinical Trial.
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES. Stringer-Reasor EM, et al. Among authors: nabell lm. Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9. Breast Cancer Res. 2021. PMID: 33663560 Free PMC article. Clinical Trial.
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. Cohen EEW, et al. Among authors: nabell l. Clin Cancer Res. 2022 Mar 15;28(6):1157-1166. doi: 10.1158/1078-0432.CCR-21-1411. Clin Cancer Res. 2022. PMID: 34965944 Free PMC article. Clinical Trial.
NCCN Task Force Report: breast cancer in the older woman.
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. Carlson RW, et al. Among authors: nabell lm. J Natl Compr Canc Netw. 2008;6 Suppl 4:S1-25; quiz S26-7. J Natl Compr Canc Netw. 2008. PMID: 18597715 Review.
60 results